SynthesisSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026
Febrile neutropenia in adults with diffuse large B-cell lymphoma receiving first-line R-CHOP-based therapy: a systematic review and meta-analysis of observational and trial evidence.
Synthesis in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionFebrile neutropenia (FN) is an important complication of first-line immunochemotherapy for diffuse large B-cell lymphoma (DLBCL). Thresholds for primary granulocyte colony-stimulating factor (G-CSF) prophylaxis are risk-based, but the FN burden in routine practice is uncertain, and whether trial-derived estimates describe it is unknown.
methodsSystematic review and meta-analysis of proportions. MEDLINE, CENTRAL, ClinicalTrials.gov, Europe PMC, Epistemonikos, Lens.org, Google Scholar, and citation tracking were searched from inception to 8 September 2026. Eligible studies reported FN incidence in adults with DLBCL receiving first-line R-CHOP or R-CHOP-like therapy. Analyses were stratified by design, because observational cohorts and trials measure FN under materially different conditions. Risk of bias and certainty were assessed using ROBINS-I/RoB 2 and GRADE.
resultsFifteen studies (5440 patients; 885 FN events) were included. Across ten observational cohorts (4020 patients), pooled FN incidence was 19.0% (95% CI 17.1-21.1; I
conclusionIn routine practice, approximately one in five adults with DLBCL receiving first-line R-CHOP-based therapy develops FN-an incidence at, rather than below, the conventional 20% threshold for primary G-CSF prophylaxis. Trial-derived estimates should not be assumed to represent this burden.
Indexed as
Identifiers
42839187What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.